C R Bard Inc (NYSE:BCR) Shares Sold by CHURCHILL MANAGEMENT Corp

CHURCHILL MANAGEMENT Corp cut its stake in shares of C R Bard Inc (NYSE:BCR) by 3.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,302 shares of the medical instruments supplier’s stock after selling 650 shares during the quarter. CHURCHILL MANAGEMENT Corp’s holdings in C R Bard were worth $6,062,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in BCR. KCM Investment Advisors LLC lifted its holdings in C R Bard by 0.5% in the 2nd quarter. KCM Investment Advisors LLC now owns 2,187 shares of the medical instruments supplier’s stock worth $691,000 after purchasing an additional 10 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its holdings in C R Bard by 3.3% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 4,901 shares of the medical instruments supplier’s stock worth $1,571,000 after purchasing an additional 156 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in C R Bard by 10.3% in the 3rd quarter. Pacer Advisors Inc. now owns 1,671 shares of the medical instruments supplier’s stock worth $536,000 after purchasing an additional 156 shares in the last quarter. Monroe Bank & Trust MI raised its holdings in shares of C R Bard by 65.6% during the 3rd quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock worth $100,000 after acquiring an additional 177 shares in the last quarter. Finally, Global X MANAGEMENT CO LLC raised its holdings in shares of C R Bard by 11.6% during the 3rd quarter. Global X MANAGEMENT CO LLC now owns 1,821 shares of the medical instruments supplier’s stock worth $584,000 after acquiring an additional 189 shares in the last quarter. Institutional investors own 79.11% of the company’s stock.

Shares of C R Bard Inc (NYSE:BCR) traded down $1.95 during trading on Thursday, reaching $331.24. The company’s stock had a trading volume of 4,714,800 shares, compared to its average volume of 679,456. The company has a market cap of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.57. C R Bard Inc has a 12 month low of $222.42 and a 12 month high of $337.73.

C R Bard (NYSE:BCR) last announced its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million for the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. C R Bard’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.64 EPS. equities analysts anticipate that C R Bard Inc will post 11.89 EPS for the current year.

Several analysts have recently issued reports on the company. Cowen reaffirmed a “hold” rating and set a $317.00 price objective on shares of C R Bard in a report on Friday, November 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of C R Bard in a report on Thursday, October 26th. ValuEngine cut C R Bard from a “buy” rating to a “hold” rating in a report on Friday, December 1st. Barclays upped their price objective on C R Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a report on Monday, November 6th. Finally, Zacks Investment Research raised C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price on the stock in a research report on Tuesday, December 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company’s stock. C R Bard presently has an average rating of “Hold” and a consensus price target of $311.43.

In other news, Director David M. Barrett sold 3,344 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $327.31, for a total transaction of $1,094,524.64. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Betty D. Larson sold 5,906 shares of the stock in a transaction on Friday, October 20th. The stock was sold at an average price of $330.16, for a total value of $1,949,924.96. Following the transaction, the vice president now directly owns 10,753 shares in the company, valued at approximately $3,550,210.48. The disclosure for this sale can be found here. Insiders sold a total of 120,508 shares of company stock worth $40,143,792 in the last ninety days. 0.80% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “C R Bard Inc (NYSE:BCR) Shares Sold by CHURCHILL MANAGEMENT Corp” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/01/18/churchill-management-corp-sells-650-shares-of-c-r-bard-inc-bcr.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply